Senores Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
158.77
Cr.
PAT
30.12
Cr.
EBITDA
46.82
Cr.
Senores Pharmaceuticals Ltd. Q2FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 153.36 | 130.30 | 114.21 | 103.02 | 98.26 |
| Total Income From Operations (Cr.) | 161.76 | 137.99 | 114.21 | 103.02 | 100.63 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 46.82 | 31.53 | 25.98 | 26.65 | 21.22 |
| P/L Before Exceptional Items & Tax (Cr.) | 40.63 | 26.49 | 20.68 | 20.49 | 15.95 |
| P/L After Tax from Ordinary Activities (Cr.) | 30.12 | 21.18 | 17.97 | 16.43 | 13.04 |
| Net Profit/Loss For the Period (Cr.) | 30.12 | 21.18 | 17.97 | 16.43 | 13.04 |
| Basic EPS | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 |
FAQs
Senores Pharmaceuticals Ltd. announced its quarterly results for Q2 FY2026 on November 6, 2025.
In Q2 FY2026, Senores Pharmaceuticals Ltd. are as follows:
Revenue: ₹158.77 crore
Net Profit: ₹30.12 crore.
For Q2 FY2026, Senores Pharmaceuticals Ltd. posted ₹158.77 crore in revenue and ₹30.12 crore in net profit.
Past quarterly results for Senores Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.